Revance Therapeutics Inc. (NASDAQ:RVNC) went down by -3.43% from its latest closing price compared to the recent 1-year high of $34.22. The company’s stock price has collected 15.45% of gains in the last five trading sessions. Barron’s reported on 09/08/22 that FDA Approves New Botox Competitor From Revance Therapeutics
Is It Worth Investing in Revance Therapeutics Inc. (NASDAQ :RVNC) Right Now?
Plus, the 36-month beta value for RVNC is at 0.66. Opinions of the stock are interesting as 9 analysts out of 13 who provided ratings for Revance Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $33.08, which is $0.64 above the current price. RVNC currently public float of 79.47M and currently shorts hold a 16.44% ratio of that float. Today, the average trading volume of RVNC was 1.54M shares.
RVNC’s Market Performance
RVNC stocks went up by 15.45% for the week, with a monthly jump of 68.63% and a quarterly performance of 38.47%, while its annual performance rate touched 140.95%. The volatility ratio for the week stands at 7.24% while the volatility levels for the past 30 days are set at 7.41% for Revance Therapeutics Inc. The simple moving average for the period of the last 20 days is 34.61% for RVNC stocks with a simple moving average of 61.73% for the last 200 days.
Analysts’ Opinion of RVNC
Many brokerage firms have already submitted their reports for RVNC stocks, with Morgan Stanley repeating the rating for RVNC by listing it as a “Equal-Weight.” The predicted price for RVNC in the upcoming period, according to Morgan Stanley is $27 based on the research report published on October 11th of the previous year 2022.
Goldman, on the other hand, stated in their research note that they expect to see RVNC reach a price target of $33. The rating they have provided for RVNC stocks is “Buy” according to the report published on September 22nd, 2022.
Wells Fargo gave a rating of “Equal Weight” to RVNC, setting the target price at $17 in the report published on October 25th of the previous year.
RVNC Trading at 42.40% from the 50-Day Moving Average
After a stumble in the market that brought RVNC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.44% of loss for the given period.
Volatility was left at 7.41%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares surge +64.10% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.41% upper at present.
During the last 5 trading sessions, RVNC rose by +15.45%, which changed the moving average for the period of 200-days by +58.63% in comparison to the 20-day moving average, which settled at $24.67. In addition, Revance Therapeutics Inc. saw 75.30% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at RVNC starting from Schilke Tobin, who sale 1,000 shares at the price of $31.00 back on Jan 20. After this action, Schilke Tobin now owns 57,877 shares of Revance Therapeutics Inc., valued at $31,000 using the latest closing price.
Schilke Tobin, the CFO of Revance Therapeutics Inc., sale 3,701 shares at $27.16 during a trade that took place back on Jan 09, which means that Schilke Tobin is holding 58,877 shares at $100,525 based on the most recent closing price.
Stock Fundamentals for RVNC
Current profitability levels for the company are sitting at:
- -353.06 for the present operating margin
- +44.39 for the gross margin
The net margin for Revance Therapeutics Inc. stands at -361.59. Equity return is now at value -461.50, with -44.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.